期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

STA-21治疗寻常型银屑病对P-Stat3和IL-17水平的影响 被引量：3

Influence of STA-21 on the level of P-Stat3 and IL-17 in the treatment of psoriasis vulgaris
暂未订购
导出
摘要 目的研究寻常型银屑病皮损中STA-21对磷酸化信号转导和转录激活因子-3(P-Stat3)和白介素-17(IL-17)的影响。方法利用免疫组织化学法检测STA-21治疗2周前后寻常型银屑病皮损组织中P-Stat3、IL-17的表达。结果 STA-21治疗寻常型银屑病2周后,P-Stat3和IL-17的水平下降,两者差异均有统计学意义(Z=-3.706、-4.931,P<0.01)。结论 STA-21可通过下调P-Stat3和IL-17的表达而达到治疗寻常型银屑病的目的。 Objective To investigate the influence of STA-21 on the level ofphosphorylated signal transduc- er and activator of trauscription-3 （P-Stat3） and IL-17 in the treatment of psoriasis vulgaris. Methods Immunohisto- chemical method was used for the detection of the expression of P-Stat3, IL-17 in patients with psoriasis vulgaris be- fore and after 2 weeks of STA-21 treatment. Results After 2 weeks of the treatment, P-Stat3 and IL-17 levels de- creased significantly, with statistically significant difference （Z=-3.706,-4.931, P〈0.01）. Conclusion STA-21 can down-regulate the expression of P-Stat3, IL-17, which plays the important role in the treatment of psoriasis vulgaris.
作者 卢井发 黄雪娇
机构地区 中山大学附属第一医院黄埔院区皮肤科 赣南医学院第一附属医院皮肤科
出处 《海南医学》 CAS 2013年第23期3514-3515,共2页 Hainan Medical Journal
关键词 银屑病 信号转导和转录激活因子-3 IL-17、STA-21 Psoriasis P-Stat3 IL-17 STA-21
分类号 R758.63 [医药卫生—皮肤病学与性病学]
  • 相关文献

参考文献12

  • 1卢井发,罗迪青.寻常型银屑病皮损中磷酸化信号转导和转录激活因子-3与白介素-17的表达及意义[J].中国医药导报,2012,9(28):27-29. 被引量：5
  • 2卢井发,罗迪青,曾招林,尤聪,黄雪娇.STA-21治疗寻常型银屑病的疗效观察[J].现代生物医学进展,2013,13(16):3099-3101. 被引量：2
  • 3Philipe L, Gunter B, David W, et al. World Health Organization clas- sification of tumor pathology and genetics skin tumors [M]. Lyon: IARC Press. 2006: 198-199.
  • 4Sano S, Chan KS, Carbajal S, t al. Stat3 links activatI keratino- cytcs and immunocytcs requirexl for development of psoriasis in a novel 'ansgenic mouse model [J]. Nat IVied, 2005, I I(I): 43-49.
  • 5Levy DE, Lee CK. What does Star3 do? [J]. J Clin Invest, 2002, 109 (9): I143-I 148.
  • 6孙晓慧,孙青.PSTAT3与VEGF在银屑病皮损中的表达及其意义[J].中国麻风皮肤病杂志,2008,24(7):520-522. 被引量：4
  • 7Nickoloff B J, Xin H, Nestle FO, et al. The cytokine and chemokine network in psoriasis [J]. Clin Dermatol, 2007, 25(6): 568-573.
  • 8Liu H, Moroi Y, Yasumoto S, et al. localiza- tion of activated Stat3 and hTERT protein in psoriasis vulgaris [J]. Eur J Dermatol, 2006, 6(2): 205-207.
  • 9Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 func- tion in breast cancer cells [J]. Proc Natl Acad Sci USA, 2005, 102 (13): 4700-4705.
  • 10Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic tar- get for the trealrnent of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor [J]. J Invest Dermatol, 2011, 131(1): 108-117.

二级参考文献36

  • 1叶小茵,李希清,赵敬军.复方甘草酸苷治疗寻常性银屑病疗效观察[J].中国皮肤性病学杂志,2006,20(2):128-128. 被引量：36
  • 2黎兆军,孙令,卢荣熙.血管内皮生长因子在扁平苔藓及银屑病皮损中的表达[J].中华皮肤科杂志,2006,39(11):651-653. 被引量：3
  • 3刘雪梅,王江滨,周剑建.甲氨蝶呤治疗银屑病关节炎的护理[J].现代生物医学进展,2007,7(8):1278-1279. 被引量：21
  • 4Yu H, Jove R. The SlATs of cancer- new molecular targets come of age. Nat Rev Cancer 2004;4:97- 105.
  • 5Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up -regulates VEGF expression and tumor angiogenesis. Oncogene 2002 ; 21: 2000 - 2008.
  • 6Dvorak HF, Browh LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029- 1039.
  • 7Detmar M. The role of VEGF and thrombospondins in skin anglogenesis. J Dermatol Sci 2000;24(Suppl 1) :78 - 84.
  • 8Wang S, Evera BM. Caco- 2 cell differentiation is associated with a decrease in Stat protein levels and binding. J Gastrointest Surg 1999;3:200 - 207.
  • 9Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol cell boil 2002;3:651.
  • 10Niu G, Heller R, Catlett- Falcone R, et al. Gene therapy with dominant - negative Stat3 suppresses growth of the routine B16 tumor in vivo. Cancer Res 1999;59:5059- 5063.

共引文献8

同被引文献26

  • 1Belinchon I. Vanaclocha F,de la Cueva-Dobao P,et al. Metabolicsyndrome in Spanish patients with psoriasis needing systemictherapy : prevalence and association with cardiovascular diseasein pso-risk,a cross-sectional study [J]. J Dermatolog Treat,2014,11(3):31-32.
  • 2Armstrong AW, Tuong W,Love TJ,et al. Treatments for nailpsoriasis: a systematic review by the GRAPPA nail psoriasiswork group[J]. J Rheumatol,2014,41(11) : 2306-2314.
  • 3Boehncke WH,Alvarez-Martinez D, Solomon JA,et al. Safetyand efficacy of therapies for skin symptoms of psoriasis in pa-tients with psoriatic arthritis: a systematic review[J]. J Rheu-matol,2014,41(11) :2301-2305.
  • 4王忠永,邱会芬,韩兆东,等.阿维A对银屑病患者外周血Thl7/Treg细胞及相关细胞因子表达影响研究[J].中华临床医师杂志(电子版),2013,22(1) :9984-9987.
  • 5Ebihara S,Date F.Dong Y, et al. Interleukin-17 is a critical tar-get for the treatment of ankylosing enthesitis and psoriasis-likedermatitis in mice[J]. Autoimmunity,2014,29(1) : 1-8.
  • 6钟瑞平,王茹,黄春萍.308nm准分子光与311mn窄谱中波紫外线治疗银屑病疗效观察[J].实用心脑肺血管病杂志,2013,21(11):107.
  • 7Rosenberg A,Fan H.Chiu YG,et al. Divergent gene activationin peripheral blood and tissues of patients with rheumatoid ar-thritis, psoriatic arthritis and psoriasis following infliximabtherapy[J]. PLoS One,2014,9(10) :657-658.
  • 8Rosenberg A, Fan H, Chiu YG, et al. Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following Infliximab therapy [J]. PLoS One, 2014, 9(10): e110657.
  • 9Ebihara S, Date F, Dong Y, et al. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermati- tis in mice [J]. Autoimmunity, 2015, 48(4): 259-266.
  • 10Boelmcke WH, Alvarez Martinez D, Solomori JA, et al. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review [J]. J Rhettmatol, 2014, 41 (11): 2301-2305.

引证文献3

二级引证文献3

海南医学
2013年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部